on Solti
TOP-REAL Study Employs Digital Monitoring for Breast Cancer Treatment
Solti, an academic cancer research group, unveiled the innovative TOP-REAL study at the ESMO AI & Digital Oncology 2026 congress. The study aims to explore whether digital tools can help earlier detection of toxicities in HER2-positive metastatic breast cancer patients receiving first-line treatment with trastuzumab deruxtecan plus pertuzumab.
The study, in collaboration with Unicancer and WSG, focuses on implementing proactive monitoring through electronic patient-reported outcomes, pulse oximetry, and smartwatch data. This approach aims to anticipate and manage toxicities, thereby preserving the continuity of effective cancer treatments.
Approximately 300 patients across Spain, France, and Germany are expected to participate, including individuals underrepresented in earlier trials. These measures could improve quality of life and clinical outcomes for patients during treatment.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Solti news